Avid Bioservices Inc (CDMO)

[biopharm]

March 1 2017
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129099850

August 10 2017 (just published today!!..PS Targeting patent)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133725116

___________

Lots of things happened in that 2017 timeframe ...and certainly things changed for relevant relationships formed for many involved in PS Targeting

Many IIS do not typically see the puzzle pieces till it may be too late to buy in early and at breadcrumb level but that changes

Interesting all the Merck ties as they paid many a biotech along the way ...even Aduro and Sutro and the list is long

PS Targeting combos will be combined with most all Big Pharma pipelines ...whether subcutaneously to intranasal and hopefully we get that Rae of Sunrise soon

Ryan Stafford has some interesting connections and patents ...that require PS Targeting and Avid BOD should all be voted off if they can't understand that PS Targeting should be made clear on their website

________

Stimulating an immune response through bavituximab in a phase III lung cancer study.

David E. Gerber , Joseph Shan , Ulrich Keilholz , David R. Spigel , Leora Horn , Rebecca Suk HeistRachel E. Sanborn , Paul N. Mainwaring , Chandra Prakash Belani , Martin J. Edelman
The University of Texas Southwestern Medical Center, Dallas, TX; Peregrine Pharmaceuticals, Inc., Tustin, CA; Charité Comprehensive Cancer Center, Berlin, Germany; Sarah Cannon Research Institute, Nashville, TN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Massachusetts General Hospital, Boston, MA; Providence Portland Medical Center, Portland, OR; ICON Cancer Care, South Brisbane, Australia; Penn State Hershey Cancer Institute, Hershey, PA; University of New Mexico Cancer Center, Albuquerque, NM

David E. Gerber
Honoraria - Peregrine Pharmaceuticals
Research Funding - Peregrine Pharmaceuticals
Joseph Shan
No relevant relationships to disclose
Ulrich Keilholz
No relevant relationships to disclose
David R. Spigel
No relevant relationships to disclose
Leora Horn
No relevant relationships to disclose
Rebecca Suk Heist
No relevant relationships to disclose
Rachel E. Sanborn
No relevant relationships to disclose
Paul N. Mainwaring
No relevant relationships to disclose
Chandra Prakash Belani
No relevant relationships to disclose
Martin J. Edelman
No relevant relationships to disclose

TPS8129

Background: Escape from immune surveillance is a frequent mechanism of tumor initiation, proliferation, and resistance to treatment. Bavituximab is a chimeric monoclonal antibody with immune modulating properties. Bavituximab targets exposed phosphatidylserine (PS) on tumor vascular endothelium, tumor cells and tumor derived exosomes. Exposed PS in the tumor microenvironment suppresses immune and inflammatory responses by binding to PS receptors on myeloid derived suppressor cells (MDSC) and M2 macrophages, which leads to production of anti-inflammatory cytokines such as TGF-ß and IL-10which inhibits the development of an adaptive immune response. In preclinical models, PS-targeting antibodies counter these effects, resulting in production of pro-inflammatory cytokines such as TNF-a and IL-1ß, maturation of dendritic cells and induction of tumor specific cytotoxic T lymphocyte immunity. Administration of docetaxel increases PS exposure within the tumor microenvironment and also suppresses MDSCs, thereby enhancing bavituximab's effects. In a double-blind Phase II clinical trial, bavituximab 3 mg/kg plus docetaxel was well-tolerated and demonstrated 60% improvement (11.7 vs 7.3 month) in median overall survival (OS) compared to control. Methods: In this randomized, double-blind, global Phase III clinical trial, approximately 600 pts with second-line stage IIIb/IV non-squamous NSCLC will be randomized 1:1 to receive up to six 21-day cycles of docetaxel 75 mg/m2 with placebo or bavituximab 3 mg/kg weekly until disease progression or unacceptable toxicity. Patients must have one progression on platinum doublet therapy for advanced disease. Prior maintenance or targeted therapy is allowed if only 1 progression occurred. Within each geographic region, patients will be stratified by disease stage and prior maintenance/targeted therapy. The primary endpoint is overall survivaland secondary endpoints include overall response rate (modified RECIST 1.1), progression free survival (PFS) and safety. Clinical trial information: NCT01999673.

https://apps.asco.org/coidisplay/generateAbstractCOI.aspx?abstractId=134831

_____




____